Lakefront Biotherapeutics (GLPGF) Receivables - Other (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Receivables - Other for 14 consecutive years, with $134.1 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Receivables - Other rose 12.66% year-over-year to $134.1 million in Q1 2026; TTM through Mar 2026 was $134.1 million, a 12.66% increase from a year earlier, with the FY2025 full-year figure at $143.1 million, changed 0.39% from the prior year.
• Receivables - Other was $134.1 million for Q1 2026 at Lakefront Biotherapeutics, down from $147.4 million in the prior quarter.
• Over five years, Receivables - Other peaked at $157.3 million in Q1 2024 and troughed at $119.1 million in Q1 2025.
• A 5-year average of $140.0 million and a median of $141.8 million in 2024 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other grew 24.2% in 2023 and slipped 24.3% in 2025, its largest moves.
• Over 5 years, Receivables - Other stood at $122.4 million in 2022, then gained by 24.2% to $152.0 million in 2023, then fell by 6.68% to $141.8 million in 2024, then rose by 3.95% to $147.4 million in 2025, then fell by 9.02% to $134.1 million in 2026.
• The last three Receivables - Other figures came in at $134.1 million (Q1 2026), $147.4 million (Q4 2025), and $136.8 million (Q3 2025), per Business Quant data.